Long-Term Benefits of 4-Weekly Certolizumab Pegol Combination and Monotherapy On Household Productivity and Social Participation in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study

被引：0
|
作者：
Strand, Vibeke [1 ]
Purcaru, Oana [2 ]
van Vollenhoven, Ronald F. [3 ]
Choy, Ernest [4 ]
Fleischmann, Roy [5 ]
机构：
[1] Stanford Univ, Portola Valley, CA USA
[2] UCB Pharma, Brussels, Belgium
[3] Karolinska Inst, Stockholm, Sweden
[4] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales
[5] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1318
引用
收藏
页码：S567 / S567
页数：1
相关论文
共 50 条
  • [1] LONG-TERM BENEFITS OF 4-WEEKLY CERTOLIZUMAB PEGOL COMBINATION AND MONOTHERAPY ON HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY
    Strand, V
    Purcaru, O.
    Van Vollenhoven, R.
    Choy, E.
    Fleischmann, R.
    VALUE IN HEALTH, 2012, 15 (07) : A451 - A452
  • [2] LONG-TERM BENEFITS OF 4-WEEKLY CERTOLIZUMAB PEGOL MONOTHERAPY AND COMBINATION THERAPY ON HOUSEHOLD PRODUCTIVITY AND SOCIAL PARTICIPATION IN RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
    Strand, V.
    Purcaru, O.
    van Vollenhoven, R.
    Choy, E.
    Fleischmann, R.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 441 - 442
  • [3] Long-Term Safety and Efficacy of 4-Weekly Certolizumab Pegol Combination and Monotherapy in Rheumatoid Arthritis: 5 Year Results from an Open Label Extension Study
    Fleischmann, Roy M.
    van Vollenhoven, Ronald F.
    Vencovsky, Jiri
    Alten, Rieke
    Davies, Owen
    Stach, Christian
    de Longueville, Marc
    Van Lunen, Brenda
    Choy, Ernest
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S565 - S566
  • [4] LONG-TERM SAFETY OF 4-WEEKLY CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS: 5 YEAR RESULTS FROM AN OPEN LABEL EXTENSION STUDY
    Fleischmann, R.
    van Vollenhoven, R.
    Vencovsky, J.
    Alten, R.
    Davies, O.
    Stach, C.
    de Longueville, M.
    van Lunen, B.
    Choy, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 523 - 523
  • [5] LONG-TERM SAFETY AND EFFICACY OF 4-WEEKLY CERTOLIZUMAB PEGOL MONOTHERAPY AND COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: 5-YEAR RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
    Fleischmann, R.
    van Vollenhoven, R.
    Vencovsky, J.
    Alten, R.
    Davies, O.
    Stach, C.
    de Longueville, M.
    VanLunen, B.
    Choy, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 435 - 435
  • [6] LONG-TERM BENEFITS OVER MORE THAN 4 YEARS OF CERTOLIZUMAB PEGOL COMBINATION THERAPY ON WORKPLACE AND HOUSEHOLD PRODUCTIVITY, AND PARTICIPATION IN SOCIAL ACTIVITIES IN RHEUMATOID ARTHRITIS: RESULTS FROM THE OPEN-LABEL EXTENSION STUDY OF RAPID1
    Kavanaugh, A.
    Smolen, J. S.
    Emery, P.
    Keystone, E.
    Strand, V
    Purcaru, O.
    van Vollenhoven, R.
    VALUE IN HEALTH, 2013, 16 (07) : A570 - A570
  • [7] 5-YEAR RESULTS FROM THE RAPID 1 TRIAL AND OPEN-LABEL EXTENSION: LONG-TERM SAFETY AND EFFICACY OF CERTOLIZUMAB PEGOL IN COMBINATION WITH METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
    Keystone, E.
    Landewe, R.
    van Vollenhoven, R.
    Combe, B.
    Strand, V.
    Mease, P. J.
    Shaughnessy, L.
    VanLunen, B.
    van der Heijde, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 228 - 229
  • [8] Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 (12) : 2094 - 2100
  • [9] Long Term Tolerability and Efficacy of a 4-week-administration of Certolizumab pegol as Monotherapy and Combination Therapie in rheumatoid Arthritis-5-Year-Data of an open Extension Study
    Alten, R.
    Fleischmann, R.
    van Vollenhoven, R.
    Vencovsky, J.
    Davies, O.
    Stach, C.
    de Longueville, M.
    VanLunen, B.
    Choy, E.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 111 - 111
  • [10] Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
    Keystone, Edward
    Landewe, Robert
    van Vollenhoven, Ronald
    Combe, Bernard
    Strand, Vibeke
    Mease, Philip J.
    Shaughnessy, Laura
    VanLunen, Brenda
    van der Heijde, Desiree
    ARTHRITIS AND RHEUMATISM, 2013, 65 : S596 - S597
12345